艾塞那肽治疗并发代谢综合征的儿童Prader-Willi综合征1例体会

摘要
图/表
参考文献(20)
相关文章 (4)

全文: PDF (354 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要 Prader-Willi综合征是一种极易引起儿童、青少年肥胖的基因组印记性疾病，由于过度进食、肥胖所引发的高血压、高血糖、血脂异常等代谢综合征症候群会严重影响患儿的生存率及生活质量。本文对一例经基因确诊的9岁Prader-Willi综合征并发代谢综合征的患儿使用人胰高血糖素样肽-1受体激动剂——艾塞那肽治疗前后血压、体重、生化、肝脏影像学、睡眠呼吸监测等数据进行分析。艾塞那肽治疗6个月后，患儿食欲减少，饱腹感增加，体重及体重指数下降，血压下降，低密度脂蛋白胆固醇下降，高密度脂蛋白胆固醇升高，肝脏CT值上升，呼吸暂停低通气量指数下降，耐受性好。本研究为此类患儿的治疗提供了新的可能的选择。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	方海宁于飞▲

关键词 ： Prader-Willi综合征, 代谢综合征, 艾塞那肽, 非酒精性脂肪性肝病, 阻塞性睡眠呼吸暂停低通气量综合征

Abstract：Prader-Willi syndrome is a genomic imprinting disease that is highly susceptible to childhood and adolescence obesity, multiplex syndromes of metabolic syndrome such as hypertension, hyperglycemia and dyslipidemia due to overfeeding and obesity will seriously affect the survival rate and quality of life of children. In this paper, a case of genetically diagnosed 9 years old Prader-Willi syndrome child complicated with metabolic syndrome is reported to analyse the data of blood pressure, body weight, biochemistry, liver imaging and sleep apnea monitoring before and after treatment of human glucagon like peptide -1 receptor agonist-exenatide, this child's appetite decreased and the satiety increased, body weight and body mass index decreased, blood pressure decreased and stable in the normal range, low density lipoprotein cholesterol decreased, high density lipoprotein cholesterol increased, the CT value of the liver increased, apnea hypoventilation index decreased and tolerance was good after 6 months of exenatide treatment. This study provides a new possibility for the treatment of such children.

Key words： Prader-Willi syndrome Metabolic syndrome Exenatide Nonalcoholic fatty liver disease Obstruction sleep apnea-hypopnea symdrome

通讯作者: ▲通讯作者

引用本文:

方海宁于飞▲. 艾塞那肽治疗并发代谢综合征的儿童Prader-Willi综合征1例体会[J]. 中国医药导报, 2018, 15(3): 159-162.
FANG Haining YU Fei▲. Treatment of exenatide of Prader-Willi syndrome complicated with metabolic syndrome：a case report. 中国医药导报, 2018, 15(3): 159-162.

链接本文:

http://www.yiyaodaobao.com.cn/CN/ 或 http://www.yiyaodaobao.com.cn/CN/Y2018/V15/I3/159

[1] Bajrami E，Spiroski M. Genomic imprinting [J]. Open Access Maced J Med Sci，2016，4（1）：181-184.
[2] Boland CL，Harris JB，Harris KB. Pharmacological management of obesity in pediatric patients [J]. Ann Pharmacother，2015，49（2）：220-232.
[3] Bittel DC，Butler MG. Prader-Willi syndrome：clinical genetics，cytogenetics and molecular biology [J]. Expert Rev Mol Med，2005，7（14）：1-20.
[4] Brambilla P，Crinò A，Bedogni G，et al. Metabolic syndrome in children with Prader-Willi syndrome：the effect of obesity [J]. Nutr Metb Cardiovasc Dis，2011，21（4）：269-276.
[5] Hedgeman E，Ulrichsen SP，Carter S，et al. Long-term health outcomes in patients with Prader-Willi Syndrome：a nationwide cohort study in Denmark [J]. Int J Obes （Lond），2017，41（10）：1531-1538.
[6] Seufert J. Incretins and their endocrine and metabolic functions [J]. Endocr Dev，2017，32：38-48.
[7] ten Kulve JS，Veltman DJ，van Bloemendaal L，et al. Endogenous GLP-1 mediates postprandial reductions in activation in central reward and satiety areas in patients with type 2 diabetes. [J]. Diabetologia，2015，58（12）：2688-2698.
[8] Nathan BM，Rudser KD，Abuzzahab MJ，et al. Predictors of weight-loss response with glucagon-like peptide-1 receptor agonist treatment among adolescents with severe obesity [J]. Clin Obes，2016，6（1）：73-78.
[9] Salehi P，Hsu I，Azen CG，et al. Effects of exenatide on weight and appetite in overweight adolescents and young adults with Prader-Willi syndrome [J]. Pediatr Obes，2017， 12（3）：221-228.
[10] Purtell L，Sze L，Loughnan G，et al. In adults with Prader-Willi syndrome，elevated ghrelin levels are more consistent with hyperphagia than high PYY and GLP-1 levels [J]. Neuropeptides，2011，45（4）：301-307.
[11] Ronveaux CC，Tomé D，Raybould HE，et al. Glucagon-like peptide 1 interacts with ghrelin and leptin to regulate glucose metabolism and food intake through vagal afferent neuron signaling [J]. J Nutr，2015，145（4）：672-680.
[12] Salehi P，Hsu I，Azen CG，et al. Effects of exenatide on weight and appetite in overweight adolescents and young adults with Prader-Willi syndrome [J]. Pediatr Obes，2017， 12（3）：221-228.
[13] Kang YM，Jung CH. Cardiovascular effects of Glucagon-Like Peptide-1 receptor agonists [J]. Endocrinol Metab （Seoul），2016，31（2）：258-274.
[14] Kelly AS，Metzig AM，Rudser KD，et al. Exenatide as a weight-loss therapy in extreme pediatric obesity：a randomized，controlled pilot study [J]. Obesity （Silver Spring），2012，20：364-370.
[15] Okerson T，Chilton RJ. The cardiovascular effects of GLP-1 receptor agonists [J]. Cardiovasc Ther，2012，30（3）：e146-e155.
[16] Tokuda M，Katsuno T，Ochi F，et al. Effects of exenatide on metabolic parameters/control in obese Japanese patients with type 2 diabetes [J]. Endocr J，2014，61（4）：365-372.
[17] Shao N，Kuang HY，Hao M，et al. Benefits of exenatide on obesity and non-alcoholic fatty liver disease with elevated liver enzymes in patients with type 2 diabetes [J]. Diabetes Metab Res Rev，2014，30（6）：521-529.
[18] Liu J，Wang G，Jia Y， et al. GLP-1 receptor agonists：effects on the progression of non-alcoholic fatty liver disease [J]. Diabetes Metab Res Rev，2015，31（4）：329-335.
[19] 中华医学会儿科学分会内分泌遗传代谢学组，《中华儿科杂志》编辑委员会.中国Prader—Willi综合征诊治专家共识（2015）[J].中华儿科杂志，2015，53（6）：419-424.
[20] Blackman A，Foster GD，Zammit G，et al. Effect of liraglutide 3.0 mg in individuals with obesity and moderate or severe obstructive sleep apnea：the SCALE Sleep Apnea randomized clinical trial [J]. Int J Obes（Lond），2016， 40（8）：1310-1319.